Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 1/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac Sulfide SCHEMBL29536153 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| Sulindac Sulfide SCHEMBL4780668 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| Sulindac Sulfide SCHEMBL2586650 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL15631472 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149218 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL24101275 | 0.91 | PPARG (0.86) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149214 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149223 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL30486787 | 0.91 | PPARG (0.86) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL22109319 | 0.90 | PPARG (0.81) | PPARGCYP1A2MAPTMAPK1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658877-A | Shulin acid intermediate impurity and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-111530480-B | Porous layered transition metal chalcogenide compound and preparation method and application thereof | 杭州师范大学 | 2022-11-25 | — | — | CN | claimed |
| CN-111530480-A | Porous layered transition metal chalcogenide compound and preparation method and application thereof | 杭州师范大学 | 2020-08-14 | — | — | CN | claimed |
| EP-2571497-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford-Burnham Medical Research Institute (US) | 2013-03-27 | — | — | EP | claimed |
| CN-103002887-A | Methods and compositions relating to retinoid receptor selective pathways | SANFORD BURNHAM MED RES INST | 2013-03-27 | — | — | CN | claimed |
| WO-2011140525-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-10 | — | — | WO | claimed |
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | claimed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | claimed |
| US-6355836-B1 | ISOMERIZATION PROCESS OF 5-FLUORO-2-METHYL-1(P-METHYLTHIO) BENZYLIDENE)INDENE-3-ACETIC ACID AND SODIUM SALT | ZAMBON GROUP S.P.A. (IT) | 2002-03-12 | — | — | US | claimed |
| EP-0206241-B1 | PROCESS FOR THE PREPARATION OF CIS-5-FLUORO-2-METHYL-1-(4-METHYLTHIOBENZYLIDENE)-INDENE-3-ACETIC ACID | ZAMBON S.p.A. (IT) | 1989-04-19 | — | — | EP | claimed |
| US-4748271-A | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methyl-thiobenzylidene)-indene-3-acetic acid | ZAMBON S.P.A. (IT) | 1988-05-31 | — | — | US | claimed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | claimed |
| EP-0036816-B1 | OPHTHALMIC COMPOSITION OF 5-FLUORO-2-METHYL-1-(P-METHYLTHIO-BENZYLIDENE)-3-INDENYLACETIC ACID OR SALT THEREOF | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | claimed |
| US-4423074-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylthio)phenyl]me]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | claimed |
| US-4402979-A | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid | Merck & Co., Inc. & Laboratories (US) | 1983-09-06 | — | — | US | claimed |
| US-4369182-A | Inflammation-preventing pharmaceutical composition of oral administration | A. NATTERMANN & CIE GMBH (DE) | 1983-01-18 | — | — | US | claimed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | claimed |
| CN-118853779-A | Preparation method and application of sulindac and intermediate thereof | 江苏暨明医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-117658877-A | Shulin acid intermediate impurity and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111530480-B | Porous layered transition metal chalcogenide compound and preparation method and application thereof | 杭州师范大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-111530480-A | Porous layered transition metal chalcogenide compound and preparation method and application thereof | 杭州师范大学 | 2020-08-14 | — | — | CN | disclosed |
| CN-107050007-B | Methods and compositions relating to retinoid receptor selective pathways | 桑福德 - 伯纳姆医学研究所 | 2020-06-30 | — | — | CN | disclosed |
| CN-111233706-A | Green synthesis method of sulindac | 安徽峆一药业股份有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10087156-B2 | Methods and compositions related to retinoid receptor-selective pathway | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2571497-B1 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD BURNHAM MED RES INST (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170313668-A1 | METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford Burnham Prebys Medical Discovery Institute | 2017-11-02 | — | — | US | disclosed |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-07-06 | — | — | US | disclosed |
| US-9611235-B2 | Methods and compositions related to a retinoid receptor-selective pathway | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | disclosed |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | disclosed |
| US-20160326200-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIV GEORGIA (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3080137-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | The University Of Georgia Research Foundation, Inc (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160296483-A1 | Methods and Pharmaceutical Compositions for Treatment of Cystic Fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-10-13 | — | — | US | disclosed |
| US-9402821-B2 | Methods and pharmaceutical compositions for treatment of cystic fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-08-02 | — | — | US | disclosed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | disclosed |
| US-20150266842-A1 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | US ARMY, SECRETARY OF THE ARMY | 2015-09-24 | — | — | US | disclosed |
| US-20150182480-A1 | Methods and Pharmaceutical Compositions for Treatment of Cystic Fibrosis | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2015-07-02 | — | — | US | disclosed |
| WO-2015089389-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| EP-2571497-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford-Burnham Medical Research Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| CN-103002887-A | Methods and compositions relating to retinoid receptor selective pathways | SANFORD BURNHAM MED RES INST | 2013-03-27 | — | — | CN | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011140525-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011088474-A2 | SULINDAC AND SULINDAC DERIVATIVES AND THEIR USES RELATED TO INFECTION | Zirus, Inc. (US) | 2011-07-21 | — | — | WO | disclosed |
| CN-101854922-A | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation | WARSAW ORTHOPEDIC INC | 2010-10-06 | — | — | CN | disclosed |
| EP-2065047-A1 | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein | Board of Regents, The University of Texas System (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1214940-B1 | Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein | UNIV TEXAS (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | disclosed |
| EP-1146866-B1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | disclosed |
| EP-1146866-A4 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | disclosed |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| EP-1214940-A1 | Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-0805684-B1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | UNIV TEXAS (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6355836-B1 | ISOMERIZATION PROCESS OF 5-FLUORO-2-METHYL-1(P-METHYLTHIO) BENZYLIDENE)INDENE-3-ACETIC ACID AND SODIUM SALT | ZAMBON GROUP S.P.A. (IT) | 2002-03-12 | — | — | US | disclosed |
| US-6355836-B1 | ISOMERIZATION PROCESS OF 5-FLUORO-2-METHYL-1(P-METHYLTHIO) BENZYLIDENE)INDENE-3-ACETIC ACID AND SODIUM SALT | ZAMBON GROUP S.P.A. (IT) | 2002-03-12 | — | — | US | disclosed |
| EP-1146866-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6300346-B1 | THERAPY OF PRECANCEROUS LESIONS COMPRISING ADMINISTERING INDENYL HYDROXAMIC ACID DERIVATIVE COMPOUND | CELL PATHWAYS, INC. | 2001-10-09 | — | — | US | disclosed |
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-09-06 | — | — | US | disclosed |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-07-05 | — | — | US | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6177471-B1 | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000044372-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071934-A | PREVENTING TUMORS OR SLOWING THEIR GROWTH | CELL PATHWAYS, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6025394-A | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | CELL PATHWAYS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5958982-A | Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5955451-A | NONSTEROID ANTIINFLAMMATORY AGENTS COMPLEXED WITH ZWITTERIONS OR PHOSPHOLIPIDS FOR NONIRRITATION OF GASTROINTESTINAL SYSTEMS AND ANTIPYRETICS | THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS | 1999-09-21 | — | — | US | disclosed |
| US-5902827-A | Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS (US) | 1999-05-11 | — | — | US | disclosed |
| US-5776962-A | Lactone compounds for treating patient with precancerous lesions | CELL PATHWAYS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5763422-A | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998013073-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5696159-A | Lactone compounds for treating patients with precancerous lesions | CELL PATHWAYS, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-5093356-A | Antiallergens, antiasthma, antiinflammatory, cytoprotective | MERCK FROSST CANADA, INC. (CA) | 1992-03-03 | — | — | US | disclosed |
| EP-0206241-B1 | PROCESS FOR THE PREPARATION OF CIS-5-FLUORO-2-METHYL-1-(4-METHYLTHIOBENZYLIDENE)-INDENE-3-ACETIC ACID | ZAMBON S.p.A. (IT) | 1989-04-19 | — | — | EP | disclosed |
| US-4748271-A | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methyl-thiobenzylidene)-indene-3-acetic acid | ZAMBON S.P.A. (IT) | 1988-05-31 | — | — | US | disclosed |
| US-4748271-A | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methyl-thiobenzylidene)-indene-3-acetic acid | ZAMBON S.P.A. (IT) | 1988-05-31 | — | — | US | disclosed |
| US-4748271-A | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methyl-thiobenzylidene)-indene-3-acetic acid | ZAMBON S.P.A. (IT) | 1988-05-31 | — | — | US | disclosed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | disclosed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | disclosed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | disclosed |
| US-4528193-A | Inflammation-preventing pharmaceutical composition of oral administration | A. NATTERMAN & CIE. GMBH (DE) | 1985-07-09 | — | — | US | disclosed |
| EP-0036816-B1 | OPHTHALMIC COMPOSITION OF 5-FLUORO-2-METHYL-1-(P-METHYLTHIO-BENZYLIDENE)-3-INDENYLACETIC ACID OR SALT THEREOF | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4423074-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylthio)phenyl]me]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | disclosed |
| US-4423074-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylthio)phenyl]me]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | disclosed |
| US-4421747-A | PHOSPHOLIPID AND DERIVATIVE OF PHENYLACETIC OR PHENYLPROPIONIC ACID | A. NATTERMANN & CIE. GMBH (DE) | 1983-12-20 | — | — | US | disclosed |
| US-4402979-A | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid | Merck & Co., Inc. & Laboratories (US) | 1983-09-06 | — | — | US | disclosed |
| US-4402979-A | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid | Merck & Co., Inc. & Laboratories (US) | 1983-09-06 | — | — | US | disclosed |
| US-4402979-A | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid | Merck & Co., Inc. & Laboratories (US) | 1983-09-06 | — | — | US | disclosed |
| US-4378354-A | CONSISTING OF A PHOSPHOLIPID AND SALICYLIC ACID OR DERIVATIVE | A. NATTERMANN & CIE. GMBH (DE) | 1983-03-29 | — | — | US | disclosed |
| US-4369182-A | Inflammation-preventing pharmaceutical composition of oral administration | A. NATTERMANN & CIE GMBH (DE) | 1983-01-18 | — | — | US | disclosed |
| US-4332795-A | INDOLE COMPOUND AND PHOSPHOLIPID | A. NATTERMANN & CIE. GMBH (DE) | 1982-06-01 | — | — | US | disclosed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036816-A2 | Ophthalmic composition of 5-fluoro-2-methyl-1-(p-methylthio-benzylidene)-3-indenylacetic acid or salt thereof | MERCK & CO. INC. (US) | 1981-09-30 | — | — | EP | disclosed |
| US-3970693-A | Process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-07-20 | — | — | US | disclosed |
| US-3944600-A | Indenylidene-3-acetic acid process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
| US-3944600-A | Indenylidene-3-acetic acid process for preparing indene acetic acids | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | PPARG 1066/4885CYP1A2 877/4885MAPT 4774/4885 |
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, FFAR3 | PPARG 31/4885CYP1A2 3426/4885MAPT 2119/4885 |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | PPARG 832/4885CYP1A2 719/4885MAPT 1548/4885 |
| US-20170313668-A1 | METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY | RXRG, RXRB, RXRA | PPARG 77/4885CYP1A2 3693/4885MAPT 3552/4885 |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | PPARG 18/4885CYP1A2 2296/4885MAPT 4603/4885 |
| US-20160326200-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | PPARG 1066/4885CYP1A2 877/4885MAPT 4774/4885 |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | PPARG 1310/4885CYP1A2 797/4885MAPT 583/4885 |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | PPARG 151/4885CYP1A2 402/4885MAPT 2642/4885 |
| US-10087156-B2 | Methods and compositions related to retinoid receptor-selective pathway | RXRG, RXRB, RXRA | PPARG 77/4885CYP1A2 3693/4885MAPT 3552/4885 |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, IAPP | PPARG 32/4885CYP1A2 3107/4885MAPT 3451/4885 |
| US-20150266842-A1 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | RXRG, RXRB, RXRA | PPARG 43/4885CYP1A2 2827/4885MAPT 4690/4885 |
| US-20150182480-A1 | Methods and Pharmaceutical Compositions for Treatment of Cystic Fibrosis | CFTR, LIPA, SLC26A4 | PPARG 764/4885CYP1A2 1131/4885MAPT 4803/4885 |
| US-20160296483-A1 | Methods and Pharmaceutical Compositions for Treatment of Cystic Fibrosis | CFTR, LIPA, SLC26A4 | PPARG 764/4885CYP1A2 1131/4885MAPT 4803/4885 |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | PPARG 832/4885CYP1A2 719/4885MAPT 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.